Kevin Trapp - DBV Technologies Chief Commercial Officer
| DBV Stock | EUR 0.54 0.03 5.88% |
Insider
Kevin Trapp is Chief Commercial Officer of DBV Technologies SA since 2018.
| Age | 52 |
| Tenure | 6 years |
| Phone | 33 1 55 42 78 78 |
| Web | https://www.dbv-technologies.com |
DBV Technologies Management Efficiency
The company has return on total asset (ROA) of (0.2178) % which means that it has lost $0.2178 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4299) %, meaning that it generated substantial loss on money invested by shareholders. DBV Technologies' management efficiency ratios could be used to measure how well DBV Technologies manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Elsa Borghi | Nanobiotix SA | N/A | |
| Mondher MD | Innate Pharma | 65 | |
| Laurent Lannoo | Genfit | 53 | |
| Marc Bonneville | Innate Pharma | 63 | |
| Kyung NamWortman | Cellectis | 53 | |
| Pascalyne Wilson | Cellectis | N/A | |
| Emilie Desodt | Genfit | 40 | |
| Franois Romagn | Innate Pharma | 59 | |
| MSc MSc | Cellectis | 54 | |
| JeanChristophe Marcoux | Genfit | 46 | |
| Pr Prasad | Nanobiotix SA | 78 | |
| Dr MBA | Cellectis | 46 | |
| Pr Staels | Genfit | 60 | |
| Jean Epinat | Cellectis | N/A | |
| Bart Rhijn | Nanobiotix SA | N/A | |
| Laurent Levy | Nanobiotix SA | 50 | |
| Alessandro MD | Innate Pharma | N/A | |
| AnneJuliette MA | Nanobiotix SA | 49 | |
| Brandon Owens | Nanobiotix SA | N/A | |
| DVM MBA | Innate Pharma | 58 | |
| Jean Fourni | Innate Pharma | N/A | |
Management Performance
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 |
DBV Technologies Leadership Team
Elected by the shareholders, the DBV Technologies' board of directors comprises two types of representatives: DBV Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DBV. The board's role is to monitor DBV Technologies' management team and ensure that shareholders' interests are well served. DBV Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DBV Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wence Agbotounou, Chief Clinical Trial Officer | ||
| Viviane Monges, Non-Executive Independent Director | ||
| Caroline Daniere, Chief Human Resource Officer | ||
| Claire Giraut, Non-Executive Independent Director | ||
| Adam Slatter, Chief Quality Officer | ||
| Daniel Tass, CEO Director | ||
| Daniel Soland, Non-Executive Independent Director | ||
| Julie ONeill, Non-Executive Director | ||
| Hugh Sampson, Chief Scientific Officer | ||
| Pascal Wotling, Chief Technical Operations Officer | ||
| Ramzi Benamar, Chief Financial Officer | ||
| Lucie Mondoulet, Director of Research | ||
| Anne Pollak, Head Relations | ||
| Michele Robertson, Chief Legal Officer | ||
| MarieCatherine Therene, Deputy Chief Executive Officer and Responsible Pharmacist | ||
| Joseph Becker, VP Communications | ||
| Sbastien Robitaille, Chief Officer | ||
| Daniel Tasse, Chief Executive Officer, Director | ||
| Michael Goller, Non-Executive Director | ||
| Sebastien Robitaille, Chief Financial Officer | ||
| Torbjorn Bjerke, Non-Executive Independent Director | ||
| Pharis Mohideen, Chief Medical Officer | ||
| Kevin Trapp, Chief Commercial Officer | ||
| Mailys Ferrere, Non-Executive Director | ||
| Michel Rosen, Non-Executive Independent Chairman of the Board |
DBV Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DBV Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.43 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (8.04) % | |||
| Current Valuation | 51.36 M | |||
| Shares Outstanding | 93.97 M | |||
| Shares Owned By Insiders | 6.50 % | |||
| Shares Owned By Institutions | 33.06 % | |||
| Price To Earning | 7.49 X | |||
| Price To Book | 1.24 X | |||
| Price To Sales | 28.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DBV Stock
DBV Technologies financial ratios help investors to determine whether DBV Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DBV with respect to the benefits of owning DBV Technologies security.